| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers Tenders > Headlines for 2018 > News item |
Stada sets holder meeting for 1Ύ% notes due 2022 after adjournment
By Susanna Moon
Chicago, Aug. 24 Stada Arzneimittel AG has scheduled a bondholders meeting for its 300 million of 1Ύ% notes due 2022 after having failed to amend the notes due to lack of quorum.
The meeting will be held on Sept. 18 in Germany, according to a notice.
The company said on July 5 that it did not receive the requested consents to amend the notes in connection with the provision of credit support under the 2017 financing given to majority shareholder Nidda Healthcare GmbH.
Votes were cast for 4,287,000, or 1.48%, of the bonds, which meant that the vote without a meeting was inquorate.
To make the changes, Stada needed at least a majority of the bonds to be voted.
As announced on June 8, Stada was aiming to appoint a common representative and to make related mechanical amendments to the note terms.
The appointment of the common representative is meant to procure the extension of the security to the noteholders on an equal and rateable basis with Nidda Healthcare GmbH's creditors under the 2017 financing, the release said.
Stada separately was tendering for the notes and holders had tendered 15,656,000 of them in the offer that ran from June 29 until July 10.
The issuer was offering 1,000 per 1,000 principal amount plus accrued interest up to but excluding the payment date.
After the repurchase, there will be 274.07 million of the notes left outstanding.
Stada Arzneimittel is a Bad Vilbel, Germany-based company specializing in the production of generic and over-the-counter drugs.
Nidda Healthcare is a holding company controlled by Bain Capital Private Equity, LP and Cinven Partners LLP.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.